Abbott’s Ultreon 3.0 Revolutionizes Coronary Imaging with AI Approval

Abbott has achieved a significant milestone as its Ultreon™ 3.0 Software, a next-generation AI-powered coronary imaging platform, receives both U.S. FDA clearance and CE Mark approval. By integrating artificial intelligence with optical coherence tomography (OCT), the platform promises to transform how physicians address complex coronary diseases, potentially improving patient outcomes and streamlining interventions.

Ultreon 3.0 represents a groundbreaking advancement in the realm of coronary imaging, combining high-resolution OCT images with AI-driven insights to aid physicians in performing percutaneous coronary interventions (PCI) more effectively. The technology enables clinicians to accurately determine the type of plaque causing blockages, optimizing stent placement and size to improve blood flow—a crucial factor in patient recovery. With its ability to offer high-speed imaging with minimal or no contrast, the system holds particular promise for patients with kidney conditions who are more sensitive to contrast agents. The platform’s swift and precise imaging capabilities allow for a seamless workflow that could enhance decision-making during critical procedures, as emphasized by leading cardiologists in the U.S. and Europe.

Abbott’s Ultreon 3.0 sets a new precedent for coronary artery disease treatment, marrying cutting-edge imaging technology with AI to bolster clinician confidence and patient care. With its recent regulatory approvals, the system stands poised to influence cardiovascular practices on a global scale, underscoring a pivotal shift towards more informed and efficient medical procedures.